JPRN-UMIN000015049已完成2 期
Phase 2 trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancer - ERIS-Study
Advanced Clinical Research Organization0 个研究点目标入组 32 人开始时间: 2014年9月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1.patients with history of prior treatment with eribulin and S1 2.patients with infection or HBs antigen positive 3.pleural effusion, peritoneal effusion which needs drainage 4.brain metastasis with clinical symptoms 5.patients with following serious complication (1)ischemic heart disease and arrhythmic cardiac disease with poor control. (2)ischemic heart disease within 6 months, (3)liver cirrhosis, (4)watery diarrhea (5)interstitial pneumonia or pulmonary fibrosis by chest radiograph (6)bleeding tendency (7)another serious complication 6.patients with active double cancer 7.patients who need to receive continuous corticosteroid administration 8.patients with a history of widespread radiation therapy 9.pregnant or nursing women 10.patients with serious drug allergy 11.patients who are participating in the other clinical trial 12.patients judged improper to entry this trial by physician
研究者
相似试验
招募中
1 期
Phase I trial of eribulin/S-1 combination therapy for advanced/recurrent breast cancer pretreated by anthracycline and taxaneAdvanced and recurrent breast cancerJPRN-UMIN000009716Depertment of medical oncology, Kinki University Hospital, Faculty of medicine12
已完成
2 期
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who presented well-defined taxane resistanceBreast CancerJPRN-UMIN000006965Saitama Breast Cancer Clinical Study Group (SBCCSG)52
已完成
不适用
Phase II clinical trial of the combination of eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancer: observational studybreast cancerJPRN-UMIN000028594Dept. of Endocrine & Breast Surgery, Kyoto Prefectural University of Medicine30
已完成
2 期
Phase II clinical trial of the combination of eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancerAdvanced/recurrent HER2-positive breast cancerJPRN-UMIN000009890Kyoto Prefectural University of Medicine30
招募中
2 期
Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer.Advanced/recurrent HER2-positive breast cancerJPRN-UMIN000011020Sairtama Breast Cancer Clinical Study Group (SBCCSG)na35